@article{229d7048e2a14ef3a221749cfc0fbd43,
title = "A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities",
abstract = "The aim of this study was to investigate the role of mild hyperthermia (39-40 °C) in isolated cytostatic perfusion for patients with recurrent melanoma of the extremities. A total of 218 patients treated with mild hyperthermic perfusion was compared to 166 patients perfused under controlled normothermic conditions (37-38 °C). Only patients whose lesions had been excised before or at the moment of perfusion were eligible for this study. A variety of prognostic factors was controlled for in a Cox proportional hazards analysis. The application of mild hyperthermia did not influence limb recurrence-free interval nor survival (corrected P values 0.46 and 0.18, respectively). In this retrospective comparative study, no benefit for mild hyperthermia in regional isolated perfusion could be identified.",
keywords = "melphalan, mild hyperthermia, recurrent melanoma, regional isolated perfusion",
author = "Klaase, {J. M.} and Kroon, {B. B.R.} and Eggermont, {A. M.M.} and {van Geel}, {A. N.} and {Schraffordt Koops}, H. and J. Oldhoff and D. Li{\'e}nard and Lejeune, {F. J.} and R. Berkel and Franklin, {H. R.} and Hart, {A. A.M.}",
note = "Funding Information: Acknowledgements-This work was supported by the French Ligue Nationale contre le Cancer, Con% de L{\textquoteright}I&re (1993). We wish to thank Pr. C. Agnius-Delord who provided us with the information on radioimmunoassays of PSA in the Centre Hospitalier Universitaire of Grenoble, and Dr G. Charriere who gave us the same information from the Institut Pasteur in Lyon. We are also greatly indebted to Pr Rambeaud of the Urology department, who gave us access to the information on ultrasonography and needle biopsies.",
year = "1995",
doi = "10.1016/0959-8049(94)00372-C",
language = "English",
volume = "31",
pages = "58--63",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd.",
number = "1",
}